Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Lasers Med Sci ; 37(8): 3183-3191, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-35723829

RESUMO

This study aims to develop and characterize NCL loaded with ZnF16Pc (Pc) for application in antimicrobial photodynamic therapy. For the development of the NLC, the fusion-emulsification technique followed by sonication was applied. NLC and Pc-NLC were characterized in terms of mean diameter (Dm.n), polydispersity index (PdI), zeta potential (ZP), encapsulation efficiency (%EE), transmission electron microscopy (TEM), differential scanning (DSC), photobleaching and singlet oxygen generation in cellular systems (SOSG), and in vitro release assays performed by the beaker method, using dialysis membranes. Cell viability was performed by colony forming units (CFU/mL). The mean size of NLC and Pc-NLC was 158 nm ± 1.49 to 161.80 nm and showed PdI < 0.3 and ZP between -17.8 and -19.9, and stable during storage time (90 days). The TEM presented spherical particles, the Pc-NLC promoted the encapsulation of 75.57% ± 0.58. DSC analysis confirmed that there was no incompatibility between Pc and NLC. The analysis of the photodegradation profile proved to be photostable after encapsulation and this corroborates the data obtained by SOSG. In vitro release showed controlled and prolonged release. PDT Pc-NLC exhibited greater antifungal effect against C. albicans (3 log10 reduction) than Pc-NLC without light (1 log10 reduction). NLC can be an alternative to the application of Pc and improve the effect during PDT treatment.


Assuntos
Candida albicans , Nanoestruturas , Antifúngicos/farmacologia , Portadores de Fármacos/química , Portadores de Fármacos/farmacologia , Indóis , Lipídeos/química , Nanoestruturas/química , Compostos Organometálicos , Tamanho da Partícula , Oxigênio Singlete
2.
Curr Pharm Des ; 30(30): 2345-2363, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38967070

RESUMO

The incidence of breast cancer has been increasing over the last four decades, although the mortality rate has decreased. Endocrine therapy and chemotherapy are the most used options for cancer treatment but several obstacles are still attributed to these therapies. Smart materials, such as nanocarriers for targeting, delivery and release of active ingredients, sensitive to intrinsic-stimuli (pH-responsive, redox-responsive, enzyme- responsive, and thermo-responsive) and extrinsic-stimuli (ultrasound-responsive, magnetic-responsive, light-responsive) have been studied as a novel strategy in breast cancer therapy. Cyclodextrins (CDs) are used in the design of these stimuli-responsive drug carrier and delivery systems, either through inclusion complexes with hydrophobic molecules or covalent bonds with large structures to generate new materials. The present work aims to gather and integrate recent data from in vitro and in vivo preclinical studies of CD-based stimuli- responsive systems to contribute to the research in treating breast cancer. All drug carriers showed high in vitro release rates in the presence of a stimulus. The stimuli-responsive nanoplatforms presented biocompatibility and satisfactory results of IC50, inhibition of cell viability and antitumor activity against several breast cancer cell lines. Additionally, these systems led to a significant reduction in drug dosages, which encouraged possible clinical studies for better alternatives to traditional antitumor therapies.


Assuntos
Antineoplásicos , Neoplasias da Mama , Ciclodextrinas , Sistemas de Liberação de Medicamentos , Ciclodextrinas/química , Ciclodextrinas/farmacologia , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Humanos , Antineoplásicos/farmacologia , Antineoplásicos/química , Antineoplásicos/administração & dosagem , Feminino , Portadores de Fármacos/química , Sobrevivência Celular/efeitos dos fármacos , Animais , Proliferação de Células/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais
3.
Photodiagnosis Photodyn Ther ; 32: 102032, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33017659

RESUMO

Phthalocyanines are second-generation photosensitizers with photophysical and photochemical properties improved, in comparison to the first-generation. Also, these have shown to be phototoxic against several types of microorganisms and tumor cells. However, challenges such as low solubility in the physiological environment make its single administration unfeasible. Therefore, this review discusses a unique combination of phthalocyanine-loaded in drug delivery carriers for photodynamic therapy in different pathologies' treatment, including nanoemulsion, liposomes, and lipid nanoparticles in an attempt to overcome low solubility drawback. Furthermore, the latest advances to elucidating its mechanisms of action are shown. Subsequently, the manuscript was divided into ten different types of phthalocyanines for medical applications, with a description of their definitions and applications, summarizing the latest preclinical results founded in recent literature.


Assuntos
Indóis , Fotoquimioterapia , Fármacos Fotossensibilizantes , Indóis/farmacologia , Indóis/uso terapêutico , Isoindóis , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/farmacologia , Fármacos Fotossensibilizantes/uso terapêutico , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA